266 related articles for article (PubMed ID: 15616893)
1. Vitamin K2 inhibits glucocorticoid-induced bone loss partly by preventing the reduction of osteoprotegerin (OPG).
Sasaki N; Kusano E; Takahashi H; Ando Y; Yano K; Tsuda E; Asano Y
J Bone Miner Metab; 2005; 23(1):41-7. PubMed ID: 15616893
[TBL] [Abstract][Full Text] [Related]
2. Changes in osteoprotegerin and markers of bone metabolism during glucocorticoid treatment in patients with chronic glomerulonephritis.
Sasaki N; Kusano E; Ando Y; Nemoto J; Iimura O; Ito C; Takeda S; Yano K; Tsuda E; Asano Y
Bone; 2002 Jun; 30(6):853-8. PubMed ID: 12052453
[TBL] [Abstract][Full Text] [Related]
3. Increased bone resorption in HD patients: is it caused by elevated RANKL synthesis?
Avbersek-Luznik I; Balon BP; Rus I; Marc J
Nephrol Dial Transplant; 2005 Mar; 20(3):566-70. PubMed ID: 15665031
[TBL] [Abstract][Full Text] [Related]
4. Osteoclastic function is accelerated in male patients with type 2 diabetes mellitus: the preventive role of osteoclastogenesis inhibitory factor/osteoprotegerin (OCIF/OPG) on the decrease of bone mineral density.
Suzuki K; Kurose T; Takizawa M; Maruyama M; Ushikawa K; Kikuyama M; Sugimoto C; Seino Y; Nagamatsu S; Ishida H
Diabetes Res Clin Pract; 2005 May; 68(2):117-25. PubMed ID: 15860239
[TBL] [Abstract][Full Text] [Related]
5. Regulatory effect of parathyroid hormone on sRANKL-osteoprotegerin in hemodialysis patients with renal bone disease.
Doumouchtsis K; Perrea D; Doumouchtsis S; Tziamalis M; Poulakou M; Vlachos I; Kostakis A
Ther Apher Dial; 2009 Feb; 13(1):49-55. PubMed ID: 19379170
[TBL] [Abstract][Full Text] [Related]
6. Serum osteoprotegerin levels in patients after liver transplantation and correlation to bone turnover, bone mineral density and fracture status.
Fahrleitner A; Prenner G; Kniepeiss D; Iberer F; Tscheliessnigg KH; Piswanger-Sölkner C; Obermayer-Pietsch B; Leb G; Dobnig H
Wien Klin Wochenschr; 2002 Aug; 114(15-16):717-24. PubMed ID: 12602117
[TBL] [Abstract][Full Text] [Related]
7. Glucocorticoid decreases circulating osteoprotegerin (OPG): possible mechanism for glucocorticoid induced osteoporosis.
Sasaki N; Kusano E; Ando Y; Yano K; Tsuda E; Asano Y
Nephrol Dial Transplant; 2001 Mar; 16(3):479-82. PubMed ID: 11239019
[TBL] [Abstract][Full Text] [Related]
8. Pamidronate is an effective treatment for osteoporosis in patients with beta-thalassaemia.
Voskaridou E; Terpos E; Spina G; Palermos J; Rahemtulla A; Loutradi A; Loukopoulos D
Br J Haematol; 2003 Nov; 123(4):730-7. PubMed ID: 14616979
[TBL] [Abstract][Full Text] [Related]
9. Osteoprotegerin and bone mineral density in hemodiafiltration patients.
Crisafulli A; Romeo A; Floccari F; Aloisi E; Atteritano M; Cincotta M; Aloisi C; Pizzoleo MA; Ruello A; Artemisia A; Valenti A; Frisina N; Teti D; Buemi M
Ren Fail; 2005; 27(5):531-9. PubMed ID: 16152990
[TBL] [Abstract][Full Text] [Related]
10. The contribution of serum osteoprotegerin to bone mass and vertebral fractures in postmenopausal women.
Mezquita-Raya P; de la Higuera M; García DF; Alonso G; Ruiz-Requena ME; de Dios Luna J; Escobar-Jiménez F; Muñoz-Torres M
Osteoporos Int; 2005 Nov; 16(11):1368-74. PubMed ID: 15711777
[TBL] [Abstract][Full Text] [Related]
11. Tartrate-resistant acid phosphatase isoform 5b: a novel serum marker for monitoring bone disease in multiple myeloma.
Terpos E; de la Fuente J; Szydlo R; Hatjiharissi E; Viniou N; Meletis J; Yataganas X; Goldman JM; Rahemtulla A
Int J Cancer; 2003 Sep; 106(3):455-7. PubMed ID: 12845688
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the effects of genistein and zoledronic acid on the bone loss in OPG-deficient mice.
Liu J; Xu K; Wen G; Guo H; Li S; Wu X; Dai R; Sheng Z; Liao E
Bone; 2008 May; 42(5):950-9. PubMed ID: 18337202
[TBL] [Abstract][Full Text] [Related]
13. Osteoprotegerin and bone mass in squamous cell head and neck cancer patients.
Valero C; Olmos JM; Rivera F; Hernández JL; Vega ME; Macías JG
Calcif Tissue Int; 2006 Jun; 78(6):343-7. PubMed ID: 16830204
[TBL] [Abstract][Full Text] [Related]
14. Anabolic action of parathyroid hormone is skeletal site specific at the tissue and cellular levels in mice.
Iida-Klein A; Zhou H; Lu SS; Levine LR; Ducayen-Knowles M; Dempster DW; Nieves J; Lindsay R
J Bone Miner Res; 2002 May; 17(5):808-16. PubMed ID: 12009011
[TBL] [Abstract][Full Text] [Related]
15. Serum osteoprotegerin and its relationship with bone mineral density and markers of bone turnover.
Indridason OS; Franzson L; Sigurdsson G
Osteoporos Int; 2005 Apr; 16(4):417-23. PubMed ID: 15776220
[TBL] [Abstract][Full Text] [Related]
16. Mineral-bone metabolism markers in young hemodialysis patients.
Osorio A; Ortega E; Torres JM; Sanchez P; Ruiz-Requena E
Clin Biochem; 2011 Dec; 44(17-18):1425-8. PubMed ID: 21933667
[TBL] [Abstract][Full Text] [Related]
17. Serum osteoprotegerin and RANKL levels in chronic alcoholic liver disease.
García-Valdecasas-Campelo E; González-Reimers E; Santolaria-Fernández F; De la Vega-Prieto MJ; Milena-Abril A; Sánchez-Pérez MJ; Martínez-Riera A; Gómez-Rodríguez Mde L
Alcohol Alcohol; 2006; 41(3):261-6. PubMed ID: 16476762
[TBL] [Abstract][Full Text] [Related]
18. Osteoprotegerin and bone turnover markers in heavily pretreated HIV-infected patients.
Seminari E; Castagna A; Soldarini A; Galli L; Fusetti G; Dorigatti F; Hasson H; Danise A; Guffanti M; Lazzarin A; Rubinacci A
HIV Med; 2005 May; 6(3):145-50. PubMed ID: 15876279
[TBL] [Abstract][Full Text] [Related]
19. Increased levels of osteoprotegerin in hemodialysis patients.
Avbersek-Luznik I; Malesic I; Rus I; Marc J
Clin Chem Lab Med; 2002 Oct; 40(10):1019-23. PubMed ID: 12476941
[TBL] [Abstract][Full Text] [Related]
20. Serum osteoprotegerin and renal osteodystrophy.
Coen G; Ballanti P; Balducci A; Calabria S; Fischer MS; Jankovic L; Manni M; Morosetti M; Moscaritolo E; Sardella D; Bonucci E
Nephrol Dial Transplant; 2002 Feb; 17(2):233-8. PubMed ID: 11812872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]